A detailed history of Quest Partners LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Quest Partners LLC holds 3,871 shares of TVTX stock, worth $66,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,871
Previous 14,336 73.0%
Holding current value
$66,890
Previous $118 Million 54.04%
% of portfolio
0.0%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$7.89 - $15.21 $82,568 - $159,172
-10,465 Reduced 73.0%
3,871 $54.2 Million
Q2 2024

Aug 06, 2024

BUY
$5.26 - $8.28 $53,268 - $83,851
10,127 Added 240.6%
14,336 $118 Million
Q1 2024

May 09, 2024

BUY
$7.18 - $9.82 $13,527 - $18,500
1,884 Added 81.03%
4,209 $32.5 Million
Q4 2023

Feb 09, 2024

BUY
$5.44 - $9.5 $12,648 - $22,087
2,325 New
2,325 $20.9 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.11B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Quest Partners LLC Portfolio

Follow Quest Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quest Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quest Partners LLC with notifications on news.